Transglutaminases: The missing link in nephrogenic systemic fibrosis

American Journal of Dermatopathology

Volumn 29, Issue 5, 2007, Pages 433-436

  Parsons, Amy C ^a   Yosipovitch, Gil ^a   Sheehan, Daniel J ^a   Sangüeza, Omar P ^a   Greenberg, Charles S ^b   Sane, David C ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gadolinium; Nephrogenic fibrosing dermopathy; Nephrogenic systemic fibrosis; Renal failure; Transglutaminase

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 13A; CD68 ANTIGEN; GENE PRODUCT; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRANSGLUTAMINASE 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVATION; FEMALE; FIBROBLAST; FIBROSIS; GENE EXPRESSION; HISTIOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MALE; NEPHROGENIC SYSTEMIC FIBROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN; SKIN BIOPSY; UPREGULATION;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOPSY; CASE-CONTROL STUDIES; CONTRAST MEDIA; FACTOR XIIIA; FEMALE; FIBROBLASTS; FIBROSIS; GADOLINIUM; HISTIOCYTES; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; SKIN; SKIN DISEASES; SYNDROME; TRANSGLUTAMINASES;

EID: 34648821231     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e318156e43f     Document Type: Article

References (21)

1. Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. Am J Kidney Dis. 2005;46:754-759.
2. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264-267.
3. Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology. 2007;243:148-157.
4. Yerram P, Saab G, Karuparthi PR, et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure - role of gadolinium-based contrast media in causation and beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol. 2007;2:258-263.
5. Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol. 2006;15:614-617.
6. Cowper SE, Su LD, Bhawan J, et al. Nephrogenic fibrosing dermopathy. Am J Dermatopathol. 2001;25:383-393.
7. Introcaso CE, Hivnor C, Cowper S, et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: a case series of nine patients and review of the literature. Int J Dermatol. 2007;46:447-452.
8. High WA, Ayers RA, Chandler J, et al. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21-26.
9. Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunction cross-linking enzymes that stabilize tissues. FASEB J. 1991;5:3071-3077.
10. Signorini M, Bortolotti F, Poltronieri L, et al. Human erythrocyte transglutaminase: purification and preliminary characterisation. Biol Chem Hoppe Seyler. 1988;369:275-281.
11. Jiménez SA, Artlett CM, Sandorfi N, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Arthritis Rheum. 2004;50:2660-2666.
12. Telci D, Griffin M. Tissue transglutaminase (TG2) - a wound response enzyme. Front Biosci. 2006;11:867-882.
13. Vanscheidt W, Hasler K, Wokalek H, et al. Factor XIII-deficiency in the blood of venous leg ulcer patients. Acta Derm Venereol. 1991;71:55-57.
14. Inbal A, Lubetsky A, Krapp T, et al. Impaired wound healing in factor XIII deficient mice. Thromb Haemost. 2005;94:432-437.
15. Nunes I, Gleizes P-E, Metz CN, et al. Latent transforming growth factor-β binding protein domains involved in activation and transglutaminasedependent cross-linking of latent transforming growth factor-β. J Cell Biol. 1997;136:1151-1163.
16. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol. 1990;6:597-641.
17. Thomazy V, Fesus L. Differential expression of tissue transglutaminase in human cells. An immunohistochemical sudy. Cell Tissue Res. 1989;255:215-224.
18. Gratchev A, Kzhyshkowska J, Utikal J, et al. Interleukin-4 and dexamethasone counterregulate extraceullular matrix remodeling and phagocytosis in type-2 macrophages. Scand J Immunol. 2005;61:10-17.
19. Sato H, Ogino Y, Takagi H, et al. Pharmacological profiles of high-concentration (20 μg/g) tacalcitol ointment: effects on cutaneous inflammation, epidermal proliferation, and differentiation in mice. J Dermatol. 2003;30:510-524.
20. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol. 2007;2:200-202.
21. Jeon JH, Lee HJ, Jang GY, et al. Different inhibition characteristics of intracellular transglutaminase activity by cystamine and cysteamine. Exp Mol Med. 2004;36:576-581.